Monitoring Agency confirms the use of proceeds from the preferential issue is aligned with disclosed purposes as on 30 September 2025, with ongoing disclosure to investors.
AI Assistant
Beta Drugs Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.